The invention addresses the problem of providing a method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione that is suited to industrial production. The invention provides a method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione by reacting 3-bromo-3-buten-2-one and 2-hydroxy-1,4-naphthoquinone in the presence of a solvent, then obtaining crystals of 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione by adding an alcohol-based solvent and/or water to the reaction system, and treating the crystals by using a specific adsorbent in the presence of a solvent.

The invention addresses the problem of providing a method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione that is suited to industrial production. The invention provides a method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione by reacting 3-bromo-3-buten-2-one and 2-hydroxy-1,4-naphthoquinone in the presence of a solvent, then obtaining crystals of 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione by adding an alcohol-based solvent and/or water to the reaction system, and treating the crystals by using a specific adsorbent in the presence of a solvent.

A solid form of ()-Ambrox formed by a bioconversion process.

A solid form of ()-Ambrox formed by a bioconversion process.

The present invention is directed to methods for the preparation of eremophila-1(10)-11(13)-dien-12,8-olide (EPD) and analogues thereof.

Provided are compounds and compositions that inhibit glucose-induced growth signaling and methods of using same. The compounds may be suitable to treat glycolytic cancers, such as, for example, esophageal squamous cell carcinoma (ESCC). The compounds may be used to inhibit or partially inhibit glucose-promoted tumor cell proliferation, NME-1 catalyzed histidine phosphorylation of FAK, and FAK interaction with RBI. The compounds may have the following structure:

##STR00001##

Provided are compounds and compositions that inhibit glucose-induced growth signaling and methods of using same. The compounds may be suitable to treat glycolytic cancers, such as, for example, esophageal squamous cell carcinoma (ESCC). The compounds may be used to inhibit or partially inhibit glucose-promoted tumor cell proliferation, NME-1 catalyzed histidine phosphorylation of FAK, and FAK interaction with RBI. The compounds may have the following structure:

##STR00001##

Provided are a fluorinated compound for patterning a metal or an electrode (cathode), an organic electronic element using the same, and an electronic device thereof, wherein a fine pattern of the electrode is formed by using the fluorinated compound as a material for patterning a metal or an electrode (cathode), without using a shadow mask, and it is possible to more easily apply UDC since it is easy to manufacture a transparent display having high light transmittance.

Provided are a fluorinated compound for patterning a metal or an electrode (cathode), an organic electronic element using the same, and an electronic device thereof, wherein a fine pattern of the electrode is formed by using the fluorinated compound as a material for patterning a metal or an electrode (cathode), without using a shadow mask, and it is possible to more easily apply UDC since it is easy to manufacture a transparent display having high light transmittance.

The present invention relates to an organic electronic device comprising, between an anode and a cathode, at least one layer selected from an electron injection layer, an electron transport layer or an electron generation layer, the layer comprising at least one compound of the following Formula (I), wherein the compound of Formula (I) comprises one or more moieties -(A).sub.a-L and the remaining positions marked with * are hydrogen or substituents independently selected from the group consisting of deuterium, fluorine, RF, C.sub.1-C.sub.20 linear alkyl, C.sub.3-C.sub.20 branched alkyl, C.sub.1-C.sub.12 linear fluorinated alkyl, CN, RCN, C.sub.6-C.sub.20 aryl, C.sub.2-C.sub.20 heteroaryl, (PO)R.sub.2; wherein each R is independently selected from C.sub.1-C.sub.20 linear alkyl, C.sub.1-C.sub.20 alkoxy, C.sub.1-C.sub.20 thioalkyl, C.sub.3-C.sub.20 branched alkyl, C.sub.3-C.sub.20 cyclic alkyl, C.sub.3-C.sub.20 branched alkoxy, C.sub.3-C.sub.20 cyclic alkoxy, C.sub.3-C.sub.20 branched thioalkyl, C.sub.3-C.sub.20 cyclic thioalkyl, C.sub.6-C.sub.20 aryl and C.sub.2-C.sub.20 heteroaryl; A is selected from substituted or unsubstituted C.sub.6-C.sub.24 aryl or C.sub.2-C.sub.20 heteroaryl; wherein in case that A is substituted, the respective substituents are independently selected from the group consisting of deuterium, fluorine, C.sub.1-C.sub.20 linear alkyl, C.sub.3-C.sub.20 branched alkyl, linear fluorinated C.sub.1-C.sub.12 alkyl, CN, C.sub.6-C.sub.20 aryl, and C.sub.2-C.sub.2 heteroaryl; L is selected from substituted or unsubstituted C.sub.2-C.sub.42 heteroaryl, substituted or unsubstituted C.sub.6-C.sub.24 aryl or a polar group selected from (formula (aa)), (formula (bb)) and (formula (cc)), wherein substituents, if present in the respective group L are independently selected from the group consisting of deuterium, N fluorine, C.sub.1-C.sub.20 linear alkyl, C.sub.3-C.sub.20 branched alkyl, C.sub.3-C.sub.20 cyclic alkyl, C.sub.1-C.sub.20 linear alkoxy, C.sub.3-C.sub.20 branched alkoxy, C.sub.1-C.sub.12 linear fluorinated alkyl, C.sub.1-C.sub.12 linear fluorinated alkoxy, C.sub.3-C.sub.12 branched fluorinated cyclic alkyl, C.sub.3-C.sub.12 fluorinated cyclic alkyl, C.sub.3-C.sub.12 fluorinated cycle alkoxy, CN, RCN, C.sub.6-C.sub.20 aryl, C.sub.2-C.sub.20 heteroaryl, OR, SR, (CO)R, (CO)NR.sub.2, SiR.sub.3, (SO)R (SO).sub.2R, (PO)R.sub.2; wherein each R independently selected from C.sub.1-C.sub.20 linear alkyl, C.sub.1-C.sub.20 alkoxy, C.sub.1-C.sub.20 thioalkyl, C.sub.3-C.sub.20 branched alkyl, C.sub.3-C.sub.20 cyclic alkyl, C.sub.3-C.sub.20 branched alkoxy, C.sub.3-C.sub.20 cyclic alkoxy, C.sub.3-C.sub.20 branched thioalkyl, C.sub.3-C.sub.20 cyclic thioalkyl